Form 4: Cytokinetics Director Acquires Shares Through Stock Retainer Program

Cytokinetics director John T. Henderson acquired 434 shares of common stock through the company's stock retainer program.

Summary

• John T. Henderson, a director at Cytokinetics Inc., acquired 434 shares of common stock on January 2, 2025.
• The shares were acquired at a price of $48.93 per share.
• This transaction was part of the company's Director Stock in Lieu of Cash Retainer Program.
• Following the transaction, Mr. Henderson directly owns 48,987 shares and indirectly owns 83 shares through his spouse.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, which is generally positive as it shows director engagement and alignment with shareholder interests. It is not a major event, but it is a positive indicator.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a routine filing related to insider transactions and is common for publicly traded companies. It reflects the compensation structure for board members.

Comparison to Industry Standards

• Director stock compensation is a common practice across publicly traded companies, particularly in the biotech sector.
• The use of stock in lieu of cash retainers aligns with industry standards for aligning director interests with shareholder value.
• Similar transactions are regularly reported by directors of comparable companies such as Amgen, Gilead, and Biogen.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it demonstrates director confidence in the company.

Key Dates

Keywords

Cytokinetics, Director, Stock Acquisition, Form 4, Insider Trading, Share Ownership, Stock Retainer Program